- Home
- HURN vs NVCR Comparison
HURN vs NVCR Comparison
Compare HURN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- NVCR
- Stock Information
- Founded
- HURN 2002
- NVCR 2000
- Country
- HURN United States
- NVCR Switzerland
- Employees
- HURN N/A
- NVCR N/A
- Industry
- HURN Professional Services
- NVCR Medical/Dental Instruments
- Sector
- HURN Consumer Discretionary
- NVCR Health Care
- Exchange
- HURN Nasdaq
- NVCR Nasdaq
- Market Cap
- HURN 2.6B
- NVCR 1.9B
- IPO Year
- HURN 2004
- NVCR 2015
- Fundamental
- Price
- HURN $137.16
- NVCR $18.02
- Analyst Decision
- HURN Strong Buy
- NVCR Buy
- Analyst Count
- HURN 4
- NVCR 6
- Target Price
- HURN $170.75
- NVCR $32.83
- AVG Volume (30 Days)
- HURN 186.2K
- NVCR 1.8M
- Earning Date
- HURN 07-29-2025
- NVCR 07-24-2025
- Dividend Yield
- HURN N/A
- NVCR N/A
- EPS Growth
- HURN 92.74
- NVCR N/A
- EPS
- HURN 6.67
- NVCR N/A
- Revenue
- HURN $1,525,814,000.00
- NVCR $621,711,000.00
- Revenue This Year
- HURN $11.50
- NVCR $5.56
- Revenue Next Year
- HURN $7.48
- NVCR $9.19
- P/E Ratio
- HURN $20.64
- NVCR N/A
- Revenue Growth
- HURN 8.98
- NVCR 18.27
- 52 Week Low
- HURN $96.45
- NVCR $14.17
- 52 Week High
- HURN $155.00
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- HURN 40.46
- NVCR 47.07
- Support Level
- HURN $130.72
- NVCR $16.19
- Resistance Level
- HURN $135.28
- NVCR $18.02
- Average True Range (ATR)
- HURN 3.38
- NVCR 0.88
- MACD
- HURN -0.34
- NVCR -0.04
- Stochastic Oscillator
- HURN 25.51
- NVCR 29.74
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.